Autolus Therapeutics宣布2025年第四季度初步收入为2400万美元，全年收入为7500万美元，发布2026年收入展望为1.2亿-1.35亿美元

2026-01-12 20:08

Company expects preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025
Autolus anticipates full year 2026 AUCATZYL net product revenue of $120 million to $135 million
Independent real-world AUCATZYL data from ROCCA consortium confirm high level of clinical activity with favorable safety profile
Focus for 2026 is:
- Driving AUCATZYL top line growth
- Optimizing manufacturing operation to improve gross margin and innovating on next generation manufacturing platform
- Progressing the CATULUS, LUMINA and BOBCAT trials to expand the utility of obe-cel in pediatric hem-oncology and autoimmune indications